Managed Care

 

These products are 3rd-tier bait

MANAGED CARE July 2001. © MediMedia USA
News and Commentary

These products are 3rd-tier bait

MANAGED CARE July 2001. ©MediMedia USA











More than any other classes of drugs, HMG-CoA reductase inhibitors and proton-pump inhibitors are affected by three-tier formularies. Nearly 4 in 5 HMOs that use a three-tier system will put one or more HMG-CoA reductase inhibitors for treatment of hypercholesterolemia on the third copayment tier, while more than 9 in 10 pharmacy benefit managers will do the same with at least one PPI. Pharmacy executives surveyed by the consultant Scott-Levin say high utilization and the availability of therapeutic equivalents invite use of the third tier for the three most-often-named classes. Products used to treat chronic conditions also commonly earn consideration for the highest tier.

Products routinely considered for third tier

SOURCE: BENEFIT DESIGN: HOW IT'S CHANGING MANAGED CARE, SCOTT-LEVIN, NEWTOWN, PA, JUNE 2001

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015